RxDoctor Payments Data

Julissa Lopez

Family · Yonkers, NYNPI 1326708348

Payments from drug & device makers

$730in general payments, 2019–2025

Across 24 payments — averaging $30.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$306
  • Johnson & Johnson$129
  • GSK$123
  • Exact Sciences$92
  • Merck$34
  • Pfizer$30
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$730100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company11$306
Johnson & Johnson6$129
GSK1$123
Exact Sciences3$92
Merck1$34
Pfizer1$30
Amgen1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$730 in reported general payments places this provider in the 65th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$7,400
Medicare patients
41
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$7,859
FarxigaDapagliflozin Propanediol11$5,993
JanuviaSitagliptin Phosphate11$5,898
VascepaIcosapent Ethyl13$4,324
Albuterol Sulfate HfaAlbuterol Sulfate71$3,296
LevemirInsulin Detemir11$2,320
Diclofenac Sodium14$1,990
Atorvastatin Calcium134$918
Ventolin HfaAlbuterol Sulfate11$590
Sumatriptan Succinate15$404
Metformin Hcl81$396
Meclizine Hcl31$369
FenofibrateFenofibrate Nanocrystallized24$359
Metformin Er GastricMetformin Hcl11$326
Omeprazole24$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKAnoro Ellipta$123$7,85918 claims
MerckJanuvia$34$5,89811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,883 family providers in New York.

Other family in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →